<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500628</url>
  </required_header>
  <id_info>
    <org_study_id>20150618</org_study_id>
    <nct_id>NCT02500628</nct_id>
  </id_info>
  <brief_title>Heart Rate Variability in Response to Metformin Challenge</brief_title>
  <official_title>Heart Rate Variability in Response to Metformin Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woodinville Psychiatric Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woodinville Psychiatric Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to
      familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated
      with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will
      provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then
      provide an additional sample 2 hours later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doctors need to develop tests which inexpensively and reliably evaluates brain metabolism.
      Current diagnostic tests sample other tissues which often run on different fuels (fats),
      utilize unproven and often insensitive brain imaging scanners, or sequence thousands to
      millions of base-pairs of DNA. All of these tests are expensive. None of these tests
      accurately or completely capture the interactions between the 1000s of proteins involved in
      brain metabolism.

      The investigators suspect that mathematical analysis of the resting heart rate may provide
      some insight into brain metabolism. The brain controls heart rate in response to changes in
      blood pressure and blood gases like carbon dioxide and oxygen. Tight control of heart rate is
      necessary to make sure that the brain has the right mix of fuel and air. Because the brain
      can't respond instantly to changes in its fuel supply, this system acting as a biological
      carburetor has a natural oscillatory rhythm that can be monitored just like frequencies on
      the radio.

      The investigators propose to amplify these rhythms by modestly metabolically stressing the
      brain with metformin, a inhibitor of complex 1 in the mitochondria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate Variability (Time Domain)</measure>
    <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
    <description>ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate Variability (Frequency Domain)</measure>
    <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
    <description>total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Reporting Side Effects From the Medication</measure>
    <time_frame>2 hours after ingestion</time_frame>
    <description>Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Mitochondrial Diseases</condition>
  <condition>Movement Disorders</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antipsychotic use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg orally after baseline testing of heart rate</description>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Antipsychotic use</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        EITHER chronic neurogenic pain meeting American College of Rheumatology criteria for
        fibromyalgia or previous/current exposure to antipsychotic medications

        Exclusion Criteria:

          -  recent infection,

          -  renal failure,

          -  pre-existing cardiac disease,

          -  chronic obstructive pulmonary disease

          -  inability to participate in informed consent,

          -  lack of transport to return home from study site,

          -  severe fasting intolerance or hypoglycemia,

          -  history of stroke-alike episode,

          -  uncontrolled migraine or cyclic vomiting,

          -  diabetes on insulin or sulfonylurea,

          -  non-English speaker,

          -  medications with strong effects on baseline heart rate variability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon E Berner, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woodinville Psychiatric Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodinville Psychiatric Associates</name>
      <address>
        <city>Woodinville</city>
        <state>Washington</state>
        <zip>98072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <results_first_submitted>May 29, 2017</results_first_submitted>
  <results_first_submitted_qc>December 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2018</results_first_posted>
  <last_update_submitted>December 30, 2017</last_update_submitted>
  <last_update_submitted_qc>December 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woodinville Psychiatric Associates</investigator_affiliation>
    <investigator_full_name>Jon Berner MD PhD</investigator_full_name>
    <investigator_title>Clinic Director</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>mitochondria</keyword>
  <keyword>complex 1</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>neurogenic pain</keyword>
  <keyword>diabetes</keyword>
  <keyword>tardive dyskinesia</keyword>
  <keyword>heart rate variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>7/25/2015 to 2/21/16</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fibromyalgia</title>
          <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
Metformin: 500 mg orally after baseline testing of heart rate</description>
        </group>
        <group group_id="P2">
          <title>Antipsychotic Use</title>
          <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
Metformin: 500 mg orally after baseline testing of heart rate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fibromyalgia</title>
          <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
        </group>
        <group group_id="B2">
          <title>Antipsychotic Use</title>
          <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.71" spread="12.15"/>
                    <measurement group_id="B2" value="47.61" spread="11.9"/>
                    <measurement group_id="B3" value="47.1" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate Variability (Time Domain)</title>
        <description>ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)</description>
        <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
        <population>Patients with or without fibromyalgia, with or without antipsychotic use.</population>
        <group_list>
          <group group_id="O1">
            <title>Fibromyalgia</title>
            <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
          </group>
          <group group_id="O2">
            <title>Antipsychotic Use</title>
            <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability (Time Domain)</title>
          <description>ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)</description>
          <population>Patients with or without fibromyalgia, with or without antipsychotic use.</population>
          <units>msec/msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.31"/>
                    <measurement group_id="O2" value="0.83" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between fibromyalgia and non-fibromyalgia group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate Variability (Frequency Domain)</title>
        <description>total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.</description>
        <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
        <population>patients with or without fibromyalgia. with or without antipsychotic use</population>
        <group_list>
          <group group_id="O1">
            <title>Fibromyalgia</title>
            <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
Metformin: 500 mg orally after baseline testing of heart rate</description>
          </group>
          <group group_id="O2">
            <title>Antipsychotic Use</title>
            <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
Metformin: 500 mg orally after baseline testing of heart rate</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability (Frequency Domain)</title>
          <description>total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.</description>
          <population>patients with or without fibromyalgia. with or without antipsychotic use</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.14" spread="0.29"/>
                    <measurement group_id="O2" value="-.24" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Reporting Side Effects From the Medication</title>
        <description>Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect</description>
        <time_frame>2 hours after ingestion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fibromyalgia</title>
            <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
          </group>
          <group group_id="O2">
            <title>Antipsychotic Use</title>
            <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Side Effects From the Medication</title>
          <description>Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>difference between fibromyalgia and non-fibromyalgia patients.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours after ingestion of metformin</time_frame>
      <desc>Patients provide an unstructured summary of possible side effects. Most reported none. Common side effects of GI distress or somnolence were scored as binary presence or absence</desc>
      <group_list>
        <group group_id="E1">
          <title>Fibromyalgia</title>
          <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
        </group>
        <group group_id="E2">
          <title>Antipsychotic Use</title>
          <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM
Metformin: 500 mg po after baseline testing of heart rate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI distress</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon Berner MD PhD</name_or_title>
      <organization>Woodinville Psychiatric Associates</organization>
      <phone>425-481-0429</phone>
      <email>jonbernermd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

